Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Combining RNAscope ISH and IHC for Simultaneous Detection of Viral Vector and Protein Expression in EMEA Studies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Combining RNAscope ISH and IHC for Simultaneous Detection of Viral Vector and Protein Expression in EMEA Studies

Combining RNAscope ISH and IHC for Viral Vector Biodistribution Studies

CELL & GENE | RNA | BIOLOGICS

Accurate assessment of a gene therapy candidate’s efficacy and safety requires confirming the viral vector has reached target cells and that its genetic payload is actively transcribed and translated into the therapeutic protein. This page details the technical application of combining RNAscope in situ hybridization (ISH) with immunohistochemistry (IHC) to simultaneously visualize vector nucleic acids and expressed protein within the same tissue section. This dual-detection method provides unambiguous, cell-specific data on vector tropism, transduction efficiency, and functional protein expression, which is fundamental for robust IND-enabling preclinical programs.

    What is the primary advantage of combining RNAscope ISH with IHC?

    A: The primary advantage is the ability to simultaneously detect vector-derived RNA and the resulting therapeutic protein within a single tissue section. This co-localization provides definitive evidence of successful transduction and functional expression at the individual cell level, linking vector presence directly to biological activity.

    How does this dual-staining technique support IND-enabling studies for EMEA submissions?

    A: Regulatory bodies require clear data on biodistribution, target engagement, and potential non-target tissue expression. This dual method generates precise, visually verifiable data that directly addresses these requirements, demonstrating which cell types are producing the therapeutic protein and confirming the mechanism of action.

    Can this method differentiate between vector genome and transcribed mRNA?

    A: Yes. RNAscope probes can be custom-designed to target specific sequences. Probes can be designed to bind to the transgene mRNA, confirming active transcription, or to other regions of the vector genome. This specificity is a key element in understanding the vector’s biological activity post-administration.

    What tissue preparation is required for optimal results?

    A: For optimal preservation of both RNA and protein epitopes, formalin-fixed, paraffin-embedded (FFPE) tissues are standard. Franklin Biolabs has optimized protocols for antigen retrieval and RNA probe hybridization to ensure high-quality staining and signal integrity from FFPE samples collected during GxP-compliant studies.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Correlating Vector Presence with Protein Expression

A central challenge in preclinical gene therapy development is confirming that vector biodistribution translates to functional protein expression in the intended target tissues. Quantifying vector DNA or RNA in bulk tissue homogenates provides valuable data, but it does not reveal which specific cell populations were successfully transduced. Combining highly sensitive RNAscope ISH with IHC for co-detection resolves this ambiguity.

This approach allows for the precise anatomical mapping of:

  • Vector Tropism: Identifying the specific cell types that have taken up the vector.

  • Transduction Efficiency: Visualizing the extent of transgene mRNA expression within target cell populations.

  • Functional Expression: Confirming that the mRNA is being translated into the therapeutic protein.

Strategic Application in Preclinical Development

This level of cellular resolution is instrumental in de-risking a gene therapy program ahead of clinical entry. For instance, understanding the relationship between vector serotype and cellular transduction is key to optimizing delivery, a principle demonstrated in studies evaluating rAAV gene transfer in complex tissues (PMID: 22849678). By visualizing the outcome at a cellular level, we can more effectively select candidates with the desired expression profile.

Similarly, for therapies that incorporate regulated expression systems, this technique provides direct visual proof of pharmacological control. Confirming that protein expression corresponds with the administration of an inducing agent is a powerful method for validating the therapy’s mechanism of action and safety profile (PMID: 12161190).

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

GxP-Compliant Histology for Regulatory Submissions

All histology and pathology services at Franklin Biolabs are performed within a GxP framework to ensure data integrity for regulatory filings. Our work is conducted in a >100,000 sq ft facility designed for complex in vivo studies, supported by a robust animal welfare program compliant with USDA regulations. By generating high-resolution biodistribution and expression data, we provide the clear, interpretable results needed to support an 18-24 month IND timeline. Our integrated approach delivers rapid pathology insights accelerating preclinical readouts.

)

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities